Q BioMed (QBIO) 10-Q 28 Jul 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	May 31, 2022	Jul. 21, 2022
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	May 31, 2022
Entity File Number	000-55535
Entity Registrant Name	Q BIOMED INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	30-0967746
Entity Address, Address Line One	c/o Ortoli Rosenstadt LLP
Entity Address, Address Line Two	366 Madison Avenue
Entity Address, Address Line Three	3rd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	588-0022
Title of 12(b) Security	None
Trading Symbol	QBIO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		41,249,603
Entity Central Index Key	0001596062
Current Fiscal Year End Date	--11-30
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	May 31, 2022	Nov. 30, 2021
Current assets:
Cash	$ 27,167	$ 344,009
Accounts receivable	74,312	80,097
Inventory	22,425	22,253
Prepaid expenses and other current assets	21,184	13,121
Total current assets	145,088	459,480
Intangible assets, net	325,000	350,000
Total Assets	470,088	809,480
Current liabilities:
Accounts payable	1,951,781	1,345,319
Accrued expenses	1,038,403	954,309
Accrued expenses - related party	221,000	71,500
Accrued interest payable	160,439	70,677
Debt	3,415,445	3,053,037
Derivative liabilities	774,051
Total current liabilities	7,561,119	5,494,842
Total Liabilities	7,561,119	5,494,842
Commitments and Contingencies (Note 6)
Stockholders' Deficit:
Preferred stock
Common stock, $0.001 par value; 250,000,000 shares authorized; 39,222,374 and 28,647,788 shares issued and outstanding as of May 31, 2022 and November 30, 2021, respectively	39,222	28,648
Additional paid-in capital	54,947,369	53,335,901
Accumulated deficit	(67,603,161)	(64,126,618)
Total Stockholders' Deficit	(7,091,031)	(4,685,362)
Total Liabilities and Stockholders' Deficit	470,088	809,480
Convertible Series A Preferred Stock
Stockholders' Deficit:
Preferred stock	2,160,916	2,161,195
Convertible Series B Preferred Stock
Stockholders' Deficit:
Preferred stock	$ 3,364,623	$ 3,915,512

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	May 31, 2022	Nov. 30, 2021
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	39,222,374	28,647,788
Common stock, shares outstanding	39,222,374	28,647,788
Convertible Series A Preferred Stock
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	227,998	227,998
Preferred stock, outstanding	227,998	227,998
Convertible Series B Preferred Stock
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	345,000	400,000
Preferred stock, outstanding	345,000	400,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021
Condensed Consolidated Statements of Operations
Net Sales	$ 170,487	$ 45,000	$ 245,546	$ 45,000
Cost of sales	72,751	46,400	146,696	86,993
Gross income (loss)	97,736	(1,400)	98,850	(41,993)
Operating expenses:
General and administrative expenses	1,019,168	1,519,660	2,115,468	3,656,992
Research and development expenses	13,052	291,940	82,320	465,370
Total operating expenses	1,032,220	1,811,600	2,197,788	4,122,362
Loss from operations	(934,484)	(1,813,000)	(2,098,938)	(4,164,355)
Other (income) expenses:
Interest expense	454,357	85,209	868,734	135,334
Change in fair value of derivatives	(118,012)	10,072	117,805	27,473
Loss on debt extinguishment	0	0	232,100	56,122
Settlement on registration liability	0	0	241,875	0
Total other expenses	336,345	95,281	1,460,514	218,929
Net loss	(1,270,829)	(1,908,281)	(3,559,452)	(4,383,284)
Accumulated dividend on convertible preferred stock	(113,639)	(113,639)	(250,032)	(250,032)
Deemed dividend for induced conversion of convertible preferred stock	(507,927)	0	(507,927)	0
Net loss attributable to common stockholders	$ (1,892,395)	$ (2,021,920)	$ (4,317,411)	$ (4,633,316)
Net loss per share - basic	$ (0.06)	$ (0.08)	$ (0.14)	$ (0.18)
Net loss per share - diluted	$ (0.06)	$ (0.08)	$ (0.14)	$ (0.18)
Weighted average shares outstanding, basic	33,005,113	26,283,700	31,318,793	25,473,236
Weighted average shares outstanding, diluted	33,005,113	26,283,700	31,318,793	25,473,236

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Preferred stock Series A convertible preferred stock	Preferred stock Series B convertible preferred stock	Common Stock	Additional Paid in Capital Adoption of ASU 2020-06	Additional Paid in Capital	Accumulated Deficit Adoption of ASU 2020-06	Accumulated Deficit	Adoption of ASU 2020-06	Total
Beginning balance, Shares at Nov. 30, 2020	227,998	503,134	23,816,489
Beginning balance, Amount at Nov. 30, 2020	$ 2,161,980	$ 4,968,368	$ 23,816		$ 47,656,423		$ (55,886,068)		$ (1,075,481)
Issuance Of Common Stock For Cash			$ 100		99,900				100,000
Issuance of common stock for cash (in shares)			100,000
Accumulated dividend on preferred stock	90,921	159,111			(250,032)
Issuance common stock for dividend payment on preferred stock	$ (91,199)	(180,627)	$ 255		271,571
Issuance common stock for dividend payment on preferred stock (in shares)			255,013
Issuance of common stock and warrants for cash			$ 1,213		908,787				910,000
Issuance of common stock and warrants for cash (in shares)			1,213,333
Issuance of common stock to convert notes payable			$ 168		202,846				203,014
Issuance of common stock to convert notes payable (in shares)			167,780
Issuance Of Common Stock To Convert Series B Preferred Stock		$ (1,031,340)	$ 1,245		1,030,095
Issuance of common stock to convert Series B preferred stock (in shares)		(103,134)	1,245,089
Issuance Cost Related To Issuance Of Convertible Notes			$ 35		34,790				34,825
Issuance cost related to issuance of convertible notes (in shares)			35,000
Beneficial conversion feature related to convertible notes					65,217				65,217
Share based compensation for services, Amount			$ 624		1,952,959				1,953,583
Share based compensation for services, Shares			623,808
Reclassification of warrants and options from equity to liability due to reassessment under ASC 815									0
Net loss							(4,383,284)		(4,383,284)
Ending balance, Shares at May. 31, 2021	227,998	400,000	27,456,512
Ending balance, Amount at May. 31, 2021	$ 2,161,702	$ 3,915,512	$ 27,456		51,972,556		(60,269,352)		(2,192,126)
Beginning balance, Shares at Feb. 28, 2021	227,998	400,000	26,002,728
Beginning balance, Amount at Feb. 28, 2021	$ 2,160,966	$ 3,928,208	$ 26,002		50,459,561		(58,361,071)		(1,786,334)
Accumulated dividend on preferred stock	46,335	67,304			(113,639)
Issuance common stock for dividend payment on preferred stock	$ (45,599)	$ (80,000)	$ 120		125,479
Issuance common stock for dividend payment on preferred stock (in shares)			119,619
Issuance of common stock and warrants for cash			$ 1,213		908,787				910,000
Issuance of common stock and warrants for cash (in shares)			1,213,333
Share based compensation for services, Amount			$ 121		592,368				592,489
Share based compensation for services, Shares			120,832
Net loss							(1,908,281)		(1,908,281)
Ending balance, Shares at May. 31, 2021	227,998	400,000	27,456,512
Ending balance, Amount at May. 31, 2021	$ 2,161,702	$ 3,915,512	$ 27,456		51,972,556		(60,269,352)		(2,192,126)
Beginning balance, Shares at Nov. 30, 2021	227,998	400,000	28,647,788
Beginning balance, Amount at Nov. 30, 2021	$ 2,161,195	$ 3,915,512	$ 28,648		53,335,901		(64,126,618)		(4,685,362)
Cash proceeds from warrants modification					20,000				20,000
Accumulated dividend on preferred stock	90,921	159,111			(250,032)
Issuance common stock for dividend payment on preferred stock	$ (91,200)	(160,000)	$ 680		250,520
Issuance common stock for dividend payment on preferred stock (in shares)			680,440
Issuance of common stock and warrants for cash			$ 400		99,630				100,030
Issuance of common stock and warrants for cash (in shares)			400,000
Issuance of common stock to convert notes payable			$ 3,468		1,333,276				1,336,744
Issuance of common stock to convert notes payable (in shares)			3,467,341
Issuance Of Common Stock To Convert Series B Preferred Stock		$ (550,000)	$ 4,973		1,052,954				$ 507,927
Issuance of common stock to convert Series B preferred stock (in shares)		(55,000)	4,972,797						4,972,797
Deemed dividend for induced conversion of Series B preferred stock					(507,927)				$ (507,927)
Issuance of common stock to extinguish accrued liabilities			$ 676		73,223				73,899
Issuance of common stock to extinguish accrued liabilities (in shares)			676,627
Issuance of common stock to settle derivative liability			$ 245		53,410				53,655
Issuance of common stock to settle derivative liability (in shares)			245,000
Beneficial conversion feature related to convertible notes									0
Share based compensation for services, Amount			$ 132		223,462				223,594
Share based compensation for services, Shares			132,381
Share based compensation related to warrants modification, Amount					277,897				277,897
Share based compensation for options modification					179,436				179,436
Reclassification of warrants and options from equity to liability due to reassessment under ASC 815									(903,414)
Reclassification of warrants and options from equity to liability due to reassessment under ASC 815					(903,414)				(903,414)
Net loss							(3,559,452)		(3,559,452)
Ending balance, Shares at May. 31, 2022	227,998	345,000	39,222,374
Ending balance, Amount at May. 31, 2022	$ 2,160,916	$ 3,364,623	$ 39,222	$ (290,967)	54,947,369	$ 82,909	(67,603,161)	$ (208,058)	(7,091,031)
Beginning balance, Shares at Feb. 28, 2022	227,998	400,000	31,024,865
Beginning balance, Amount at Feb. 28, 2022	$ 2,160,181	$ 3,913,734	$ 31,025		54,397,659		(66,332,332)		(5,829,733)
Accumulated dividend on preferred stock	46,335	80,889			(127,224)
Issuance common stock for dividend payment on preferred stock	$ (45,600)	(80,000)	$ 402		125,198
Issuance common stock for dividend payment on preferred stock (in shares)			402,563
Issuance of common stock to convert notes payable			$ 1,890		280,907				282,797
Issuance of common stock to convert notes payable (in shares)			1,889,693
Issuance Of Common Stock To Convert Series B Preferred Stock		$ (550,000)	$ 4,973		1,052,954				$ 507,927
Issuance of common stock to convert Series B preferred stock (in shares)		(55,000)	4,972,797						4,972,797
Deemed dividend for induced conversion of Series B preferred stock					(507,927)				$ (507,927)
Issuance of common stock to extinguish accrued liabilities			$ 650		63,450				64,100
Issuance of common stock to extinguish accrued liabilities (in shares)			650,000
Issuance of common stock to settle derivative liability			$ 245		53,410				53,655
Issuance of common stock to settle derivative liability (in shares)			245,000
Share based compensation for services, Amount			$ 37		72,042				72,079
Share based compensation for services, Shares			37,456
Share based compensation related to warrants modification, Amount					260,878				260,878
Share based compensation for options modification					179,436				179,436
Reclassification of warrants and options from equity to liability due to reassessment under ASC 815					(903,414)				(903,414)
Net loss							(1,270,829)		(1,270,829)
Ending balance, Shares at May. 31, 2022	227,998	345,000	39,222,374
Ending balance, Amount at May. 31, 2022	$ 2,160,916	$ 3,364,623	$ 39,222	$ (290,967)	$ 54,947,369	$ 82,909	$ (67,603,161)	$ (208,058)	$ (7,091,031)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	6 Months Ended
	May 31, 2022	May 31, 2021
Cash flows from operating activities:
Net loss	$ (3,559,452)	$ (4,383,284)
Adjustments to reconcile net loss to net cash used in operating activities
Share based compensation for services	223,594	1,953,583
Share based consideration related to warrants modification	277,897	0
Share based compensation related to stock options modification	179,436	0
Change in fair value of derivative liabilities	117,805	27,473
Accretion of debt discount	743,393	109,950
Amortization expense	25,000	25,000
Settlement on registration liability	241,875	0
Loss on debt extinguishment	232,100	56,122
Changes in operating assets and liabilities:
Accounts receivable	5,785	(41,400)
Prepaid expenses and other current assets	(8,235)	(31,851)
Accounts payable and accrued expenses	944,168	406,065
Accrued interest payable	89,762	(23,376)
Net cash used in operating activities	(486,872)	(1,901,718)
Cash flows from financing activities:
Proceeds received from issuance of convertible notes, net	0	975,000
Proceeds received from issuance of common stock and warrants	100,030	1,010,000
Proceeds received from issuance of notes to related parties	0	30,000
Cash advances	50,000	0
Proceeds received for warrants modification	20,000	0
Net cash provided by financing activities	170,030	2,015,000
Net (decrease) increase in cash	(316,842)	113,282
Cash at beginning of the year	344,009	177,145
Cash at end of the year	27,167	290,427
Supplemental disclosures:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplemental disclosures for noncash investing and financing activities:
Issuance of common stock to convert notes payable and accrued interest	1,336,744	203,014
Issuance of common stock to convert Series B preferred stock	550,000	1,031,340
Deemed dividend for induced conversion of Series B preferred stock	507,927	0
Accumulated dividend on convertible preferred stock	250,032	250,032
Issuance of common stock for dividend payment on preferred stock	251,200	271,826
Issuance of common stock to extinguish accrued liabilities	73,899	0
Issuance of common stock to settle derivative liability	53,655	0
Reclassification of warrants and options from equity to liability due to reassessment under ASC 815	903,414	0
Reclassification of warrants and options from equity to liability due to reassessment under ASC 815	903,414
Adoption of ASU 2020-06	208,058	0
Beneficial conversion feature related to convertible notes	0	65,217
Offering cost	$ 0	$ 69,825

Organization of the Company and

Organization of the Company and Description of the Business	6 Months Ended
	May 31, 2022
Organization of the Company and Description of the Business
Organization of the Company and Description of the Business	Note 1 - Organization of the Company and Description of the Business Q BioMed Inc. (“Q BioMed”), and its wholly owned subsidiaries Q BioMed Cayman SEZC and QBMG Q BioMed Germany UG (collectively, the “Company”), is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or the spinoff of new public companies. The accompanying condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation and Going

Basis of Presentation and Going Concern	6 Months Ended
	May 31, 2022
Basis of Presentation and Going Concern
Basis of Presentation and Going Concern	Note 2 - Basis of Presentation and Going Concern Basis of Presentation The accompanying interim period unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. These condensed consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended November 30, 2021 that was filed with SEC on February 28, 2022. Certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for a full year. Certain prior period amounts related to Inventory within Prepaid expenses and other current assets in the accompanying unaudited condensed consolidated financial statements have been reclassified to conform to the current period presentation. There was no change to prior period current or total assets. Going Concern The accompanying condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has and is expected to incur net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters, amongst others, raise doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management will be forced to scale back the Company’s operations or cease its operations. Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. COVID 19 The impact of the worldwide spread of a novel strain of coronavirus (“COVID-19”) has been unprecedented and unpredictable, but based on the Company’s current assessment, the Company does not expect any material impact on its long-term strategic plans, operations and its liquidity due to the worldwide spread of COVID-19. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world and its assessment of the impact of COVID-19 may change. The Impact of Russian Military Action in Ukraine On February 24, 2022, Russian forces launched significant military action against Ukraine, which has resulted in conflict and disruption in the region. The Company is monitoring the conflict in Ukraine and any broader economic effects from the crisis. To date, the conflict between Russia and Ukraine has not had a material impact on the Company’s business, financial condition, or result of operations. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	May 31, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 - Summary of Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended November 30, 2021 included in the Company’s Form 10-K. Modification of Equity Classified Awards From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards. The classification of stock-based awards, including whether such instruments should be recorded as liabilities or as equity, is re-assessed on the modification date. Induced Conversion of Convertible Preferred Stock The Company accounts for gains or losses on extinguishment of equity-classified preferred stock as deemed dividends, to be included in the net loss per common stockholder used to calculate earnings per share. The difference between (1) the fair value of the consideration transferred to the holders of the preferred stock and (2) the carrying amount of the preferred stock (net of issuance costs) is subtracted from (or added to) net loss to arrive at net loss available to common stockholders in the calculation of earnings per share. Sequencing Policy The Company adopted a sequencing policy under ASC 815-40-35 (“ASC 815”) whereby in the event that reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares as a result of certain financial instruments with a potentially indeterminable number of shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive financial instruments, with the earliest financial instruments receiving the first allocation of shares. Pursuant to ASC 815, issuance of stock-based awards to the Company’s employees, nonemployees or directors recognized under ASC 718 are not subject to the sequencing policy. Any modifications of awards (e.g., options or warrants) that remain subject to vesting, or any modifications of awards that continue to be held by active employees, are not subject to the sequencing policy. Modifications of vested awards held by nonemployees are subject to the sequencing policy. Recent Accounting Standards In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 is not expected to have a material impact on our financial statements or disclosures. Recently Adopted Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company elected to early adopt this guidance on December 1, 2021, on a modified retrospective basis. The adoption resulted in approximately $291,000 decrease in additional paid in capital from the derecognition of the bifurcated equity component, $208,000 increase in debt from the derecognition of the discount associated with the bifurcated equity component and $83,000 decrease to the opening balance of accumulated deficit.

Loss per share

Loss per share	6 Months Ended
	May 31, 2022
Loss per share
Loss per share	Note 4 - Loss per share Basic net loss per share was calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive (amounts are rounded to nearest thousand). ​ ​ ​ ​ ​ ​ Potentially dilutive securities May 31, 2022 November 30, 2021 Series A convertible preferred stock ​ 2,280,000 ​ 2,280,000 Series B convertible preferred stock ​ 9,857,000 ​ 11,429,000 Common stock purchase warrants ​ 12,152,000 ​ 11,752,000 Stock Options ​ 4,450,000 ​ 4,450,000 Convertible Notes 34,928,000 4,898,000 Potentially dilutive securities 63,667,000 34,809,000 ​

Debt

Debt	6 Months Ended
	May 31, 2022
Debt
Debt	Note 5 - Debt ​ The table below summarizes outstanding debt as of May 31, 2022 and November 30, 2021 (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ May 31, 2022 November 30, 2021 Convertible Notes Payable: ​ ​ ​ ​ ​ ​ Principal value of 2021 Debentures ​ $ 2,828,000 ​ $ 3,506,000 Fair value of bifurcated contingent put option ​ 1,003,000 ​ 867,000 Debt discount ​ (466,000) ​ (1,320,000) Convertible notes payable, net ​ ​ 3,365,000 ​ ​ 3,053,000 Cash advances ​ ​ 50,000 ​ ​ — Total debt ​ $ 3,415,000 ​ $ 3,053,000 ​ Convertible Notes Payable February Debenture On February 12, 2021, the Company issued a debenture for $0.5 million (the “February Debenture”) pursuant to a securities purchase agreement with an accredited investor dated February 12, 2021. The February Debenture may be converted at any time on or prior to maturity at the lower of $1.15 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2020 Debenture, the conversion price may never be less than $1.00. The debenture has a maturity date of February 12, 2022, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The debenture bears interest at the rate of 5.5% per annum, and on issuance, the Company paid to the holder a commitment fee equal to 2% of the amount of the debenture. On January 21, 2022, the Company issued 1,055,000 shares of common stock to convert $0.5 million of outstanding debt and interest. The conversion price was reduced to $0.50. The Company recognized a loss on debt extinguishment of approximately $0.2 million as a result of the reduction of conversion price for the six months ended May 31, 2022. July Debenture On July 26, 2021, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “July Debenture”) in the principal amount of $806,250 and a warrant to purchase up to 645,000 shares of common stock (the “Warrant”) for a total purchase price of $750,000. The July Debenture has a maturity date of April 26, 2022, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The July Debenture carries an interest rate of 10% per annum, provided that any principal or interest which is not paid when due shall bear interest at the rate of 15% per annum from the due date until payment (the “Default Interest”). The Company may prepay the Debenture at 120% of the outstanding aggregate principal amount within the first 60 days of issuance and at 130% of the sum of the outstanding principal amount, the accrued and unpaid interest on the unpaid principal amount and any Default Interest from 61 to 180 days after issuance. The holder may convert the July Debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 85% of the average of the four (4) lowest VWAPs during the 20 Trading Days prior to the date of such calculation. The “Variable Conversion Price” shall equal, subject to an initial floor price of $0.35 (the “Floor Price”), the lower of $1.00 and 85% of the average of the four (4) lowest VWAPs during the 20 Trading Days prior to the date of such calculation. The initial Floor Price shall be readjusted to $0.10 if following the Issue Date, VWAP of the Company shall be less than $0.35 for a total of ten days. On December 15, 2021, the Company and the holder entered into a Mutual Release Agreement pursuant to which the holder agreed to add the $241,875 to the outstanding principal balance of July Debenture, for no consideration received by the Company, in order to resolve a breach of certain registration provisions of the securities purchase agreement. The July Debenture is past maturity and is currently in default. However, the Company has not received any default notice from the holder. During the three and six months ended May 31, 2022, the Company issued an aggregate 1,162,790 and 1,685,438 shares of common stock to convert $0.1 million and $0.3 million of outstanding debt, respectively. September Debenture On September 29, 2021 (the “Effective Date”), the Company entered into a securities purchase agreement with an accredited investor (“Lender”), pursuant to which the Company sold a convertible debenture (the “September Debenture”) in the principal amount of $2,200,000 with twelve-months term. The September Debenture includes an original issue discount of $185,000 and $15,000 for the payment of the Lender’s legal fees and carries an interest rate of 6% per annum. The Company also incurred other issuance cost of $247,350. On October 26, 2021, the September Debenture maturity date was extended for additional 3 months to December 29, 2022. The Company may prepay the September Debenture at 105% of the outstanding aggregate principal amount plus accrued interest within the first 60 days of issuance, at 112% of the outstanding aggregate principal amount plus accrued interest from 61-120 days after issuance and at 124% of the outstanding aggregate principal amount plus accrued interest from 121-180 days after issuance. The Debenture may not be prepaid after 180 days. The Lender has the right to convert all or any amount of the outstanding aggregate principal amount at any time at a fixed conversion price of $1.00 per share. The conversion price after six months shall be fixed to $0.50 per share. However, in the event the Company’s Common Stock trades below $0.50 per share for more than ten (10) consecutive trading days, the Lender is entitled to convert all or any amount of the outstanding aggregate principal amount into shares of the Company’s Common Stock at a Conversion Price for each share of Common Stock equal to 85% of the average of the 4 lowest VWAP’s in the prior 20 trading days. As a result of entering into the “September Debenture”, for which such instruments contained a variable conversion feature with no floor, the Company has adopted sequencing policy (see Note 3). On April 8, 2022, the Company issued 245,000 shares of common stock as commitment shares pursuant to the securities purchase agreement. The commitment to issue the shares was valued at the Effective Date fair value of approximately $0.2 million and recognized as an additional debt discount. The commitment is a forward contract, recognized at fair value, as a result of applying the Company’s sequencing policy, and recognized at fair value with changes in fair value recognized in the Company’s Condensed Consolidated Statements of Operations until settled on April 8, 2022. On May 12, 2022, the Company issued 726,903 shares of common stock to convert approximately $0.1 million of outstanding debt. Interest expense Interest expense, included in the accompanying Condensed Consolidated Statements of Operations, is comprised of the following for each period presented (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ For the six months ended ​ May 31, 2022 May 31, 2021 May 31, 2022 May 31, 2021 Interest expense based on the coupon interest rate of the outstanding debt ​ $ 59,000 ​ $ 15,000 ​ $ 120,000 ​ $ 25,000 Accretion of debt discount ​ ​ 391,000 ​ ​ 70,000 ​ ​ 743,000 ​ ​ 110,000 Other ​ ​ 4,000 ​ ​ — ​ ​ 5,000 ​ ​ — Total interest expense ​ $ 454,000 ​ $ 85,000 ​ $ 868,000 ​ $ 135,000 ​ Cash Advances Cash advances include cash provided by vendors or shareholders that is subject to repayment on demand.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	May 31, 2022
Commitments and Contingencies
Commitments and Contingencies	Note 6 - Commitments and Contingencies Legal Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. On March 31, 2022, the Company received a complaint filed in the Court of Common Pleas in Buck County, Pennsylvania claiming that the Company had failed to pay approximately $106,000 in fees for services provided under two master services agreements that the Company entered into with the plaintiff. Under those agreements, the plaintiff was to have provided services in connection with the promotion of the Company’s Strontium-89 product. The Company is analyzing how to respond to this recently received complaint. On July 12, 2022, the Company received notice that WSI PBG, LLC (“WSI”) filed a complaint for fees it alleges are due in the amount of $196,216 plus fees and expenses for consulting services provided by WSI as a result of a May 6, 2021 Master Professional Services Agreement. The Company has not filed an answer and is currently determining its next steps. Advisory Agreements The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which the Company agreed to issue shares of common stock as services are received. On March 11, 2022, the Company entered into an engagement letter agreement (“Agreement”) with EF Hutton, division of Benchmark Investments, LLC (“EF Hutton”) to effectuate the Corporation’s Firm Commitment Public Offering and Uplisting and to engage EF Hutton to act as the placement agent for a bridge or other private offering consisting of approximately $2 million. The Company shall be responsible for EF Hutton’s external counsel legal costs irrespective of whether the Offering is consummated or not, subject to a maximum of $50,000 in the event that there is not a Closing. Lease Agreement In December 2016, one of our subsidiaries entered into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ended in December 2019, and the Company has renewed its office lease agreement for another three years with the same terms. This agreement does not identify a specific asset and does not convey the use of substantially all of the shared office capacity. As such, this agreement does not contain a lease under ASC 842. The Company recognizes monthly license payments as incurred over the term of the arrangement. Rent expense is classified within general and administrative expenses on a straight-line basis.

Related Party Transactions

Related Party Transactions	6 Months Ended
	May 31, 2022
Related Party Transactions
Related Party Transactions	Note 7 - Related Party Transactions The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations as follows (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ For the six months ended ​ May 31, 2022 May 31, 2021 May 31, 2022 May 31, 2021 Consulting and legal expenses ​ $ 105,000 ​ $ 105,000 ​ $ 210,000 ​ $ 210,000 ​

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	May 31, 2022
Stockholders' Deficit
Stockholders' Deficit	Note 8 - Stockholders’ Deficit As of May 31, 2022 and November 30, 2021, the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of its $0.001 par value preferred stock. Preferred Shares The original issue price and the liquidation value per share, as of May 31, 2022, of each class of preferred stock is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Original Issue Price Liquidation Value ​ ​ Per Share ​ Per Share Series A Preferred Share ​ $ 10.00 ​ $ 10.20 Series B Preferred Share ​ $ 10.00 ​ $ 10.23 ​ During the three and six months ended May 31, 2022, the Company issued total 402,563 and 680,440 shares of common stock as dividend payment on Series A and Series B preferred stock, respectively. During the three and six months ended May 31, 2022, the Company issued 4,972,797 shares of common stock to convert 55,000 shares of Series B preferred stock. The difference between the carrying amount of the preferred stock and the fair value of the common stock exchanged for such preferred stock, totaled approximately $0.5 million. The difference was treated as a deemed dividend in the Condensed Consolidated Statements of Operations. The Company had accumulated dividends payable on the Preferred Shares of approximately $0.1 million as of May 31, 2022. Common Shares On February 14, 2022, the Company entered into a series of securities purchase agreements for the sale of 400,000 units at a $0.25 per unit sales price. The Company raised $100,000 in cash. Each unit consisted of one common share and one warrant to purchase one share of common stock at an exercise price of $0.50 . The common warrants issued on February 22, 2022 have a fair value of $0.28 per share, see Note 9. During the three months ended May 31, 2022, the Company issued 1,889,693 shares of common stock to convert approximately $0.2 million of outstanding debt and interest, respectively. During the six months ended May 31, 2022, the Company issued 3,467,341 shares of common stock to convert approximately $0.9 million of outstanding debt and interest and extinguished $0.2 million of embedded derivative liabilities, respectively. The Company recognized approximately $0.2 million debt extinguishment loss for the six months ended May 31, 2022. During the three months ended May 31, 2022, the Company issued 37,456 shares of the Company’s common stock to various vendors for advisory services, valued at approximately $10,000 based on the estimated fair market value of the stock on the date of grant. The Company also recognized approximately $62,000 related to the vesting of stock options and restricted awards. The $72,000 was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations for the three months ended May 31, 2022. During the six months ended May 31, 2022, the Company issued 132,381 shares of the Company’s common stock to various vendors for advisory services, valued at approximately $53,000 based on the estimated fair market value of the stock on the date of grant The company also recognized approximately $171,000 related to the vesting of stock options and restricted awards. The $224,000 was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations for the six months ended May 31, 2022.

Warrants and Options

Warrants and Options	6 Months Ended
	May 31, 2022
Warrants and Options
Warrants and Options	Summary of warrants The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services, warrants issued in conjunction with debt offering, and warrants issued as part of the units sold in the private placements, at May 31, 2022 and November 30, 2021 and the changes during the period then ended (warrants amount and intrinsic value are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Contractual ​ ​ ​ ​ ​ Warrants ​ Exercise Price ​ Life (years) ​ Intrinsic Value Outstanding at November 30, 2021 11,752,000 ​ $ 1.97 2.60 ​ $ — Issued 400,000 ​ ​ 0.50 2.73 ​ ​ — Forfeited/expired — ​ ​ — — ​ ​ — Outstanding at May 31, 2022 12,152,000 ​ $ 1.40 4.0 ​ $ — Exercisable at May 31, 2022 12,152,000 ​ $ 1.40 4.0 ​ $ — ​ Warrants issued on February 22, 2022 were classified as liabilities. The fair value of the warrants on grant date was based on the following key inputs: ​ ​ ​ ​ ​ ​ ​ February 22, 2022 Strike price ​ $ 0.50 ​ Terms (years) ​ 3.0 ​ Volatility ​ 126 % Risk-free rate ​ 1.7 % Dividend yield ​ 0.0 % ​ Modification of Warrants On February 1, 2022, the Company modified an aggregate of 245,625 warrants (the “Warrants”) that were originally granted to certain investors and consultants. The exercise price of the Warrants was reduced to $0.65 per share and the maturity dates of the Warrants were extended until August 1, 2024. The Company received $20,000 cash from one of the investors as consideration for this modification. The Company immediately recognized approximately $17,000 incremental stock-based compensation on February 1, 2022 based on the following weighted average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification ​ Strike price ​ $ 0.65 ​ $ 2.33 ​ Term (years) ​ 2.5 ​ 2.1 ​ Volatility ​ 135 % 127 % Risk-free rate ​ 1.0 % 1.0 % Dividend yield ​ 0.0 % 0.0 % ​ Between April and May 2022, the Company modified an aggregate of 4,765,807 warrants (the “Warrants”) that were originally granted to certain investors and officers during 2017 and 2021. The exercise price of the Warrants was reduced to between $0.50 and $0.65 per share and the maturity date of the Warrants were extended for an additional 5 years. The Company immediately recognized approximately $261,000 incremental stock-based compensation during the quarter ended May 31, 2022 based on the following weighted average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification Strike price ​ $ 0.51 ​ $ 1.76 ​ Term (years) ​ ​ 6.9 ​ ​ 2.1 ​ Volatility ​ ​ 118 % ​ 128 % Risk-free rate ​ ​ 2.7 % ​ 2.2 % Dividend yield ​ ​ 0.0 % ​ 0.0 % ​ The new warrants issued in February 2022 and warrant modifications, described above, resulted in reclassifying such modified warrants to purchase an aggregate of 5,411,432 common shares from equity to liability as a result of applying the reassessment under ASC 815. The warrants are subsequently recognized at fair value with changes in fair value recognized in the Company’s Condensed Consolidated Statements of Operations. ​ Summary of Options The following represents a summary of all outstanding options to purchase the Company’s common stock at May 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Remaining Contractual ​ ​ ​ ​ Options Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2021 4,450,000 ​ $ 1.13 4.0 ​ $ 1,000 Issued — ​ ​ — — ​ ​ — Forfeited/expired ​ — ​ ​ — ​ — ​ ​ — Outstanding at May 31, 2022 4,450,000 ​ $ 0.49 7.8 ​ $ — Exercisable at May 31, 2022 4,150,000 ​ $ 0.50 7.7 ​ $ — ​ Modification of Options On May 25, 2022, the Company modified an aggregate of 4,450,000 options (the “Options”) that were originally granted to officers, directors and certain consultants for services provided to the Company. The exercise price of the Options was reduced to $0.50 per share and the maturity date of the Options were extended for an additional 5 years. As of the modification date, 4,150,000 options were fully vested. The incremental aggregate stock-based compensation related to the modifications was $188,000, based on the following weighted average assumptions. The Company immediately recognized approximately $179,000 incremental stock-based compensation during the quarter ended May 31, 2022. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification Strike price ​ $ 0.49 ​ $ 1.13 Term (years) ​ 7.8 ​ 2.8 ​ Volatility ​ 117 % ​ 127 % Risk-free rate ​ 2.7 % ​ 2.4 % Dividend yield ​ 0.0 % ​ 0.0 % ​ The May 2022 options modifications, described above, resulted in reclassifying such modified vested options to purchase an aggregate of 4,150,000 common shares from equity to liability as a result of applying the Company’s sequencing policy. The options are subsequently recognized at fair value with changes in fair value recognized in the Company’s Condensed Consolidated Statements of Operations. Stock-based Compensation During the three and six months ended May 31, 2022, the Company recognized general and administrative expenses of approximately $0.2 million and $0.2 million as a result of the shares, outstanding warrants and options issued to consultants and employees, respectively. During the three and six months ended May 31, 2021, the Company recognized general and administrative expenses of approximately $1.4 million and $2.0 million as a result of the shares, outstanding warrants and options issued to consultants and employees, respectively. As of May 31, 2022, the estimated unrecognized stock-based compensation associated with these agreements is approximately $52,000 and will be fully recognized by November 30, 2022.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	May 31, 2022
Fair Value Measurements
Fair Value Measurements	Note 10 – Fair Value Measurements The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of May 31, 2022 and November 30, 2021 (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at May 31, 2022 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Fair value at ​ markets ​ observable inputs ​ unobservable inputs ​ May 31, 2022 (Level 1) (Level 2) (Level 3) Embedded derivative liabilities ​ $ 1,003,000 ​ $ — ​ $ — ​ $ 1,003,000 Derivative liabilities ​ $ 774,000 ​ $ — ​ $ — ​ $ 774,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at November 30, 2021 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Fair value at ​ markets ​ observable inputs ​ unobservable inputs ​ November 30, 2021 (Level 1) (Level 2) (Level 3) Embedded derivative liabilities ​ $ 867,000 ​ $ — ​ $ — ​ $ 867,000 ​ Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. There were no transfers between levels in the three or six months ended May 31, 2022. The Level 1 derivative liability is related to commitment to issue common shares pursuant to the September Debenture which was settled in April 2022 (see Note 5). During the three and six months ended May 31, 2022, the Company recognized $123,000 change in fair value related to Level 1 liability. The following table presents changes in Level 3 liabilities measured at fair value for the three and six months ended May 31, 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (amounts are rounded to nearest thousand). ​ ​ ​ ​ ​ ​ ​ ​ ​ Embedded Derivative Derivative ​ ​ Liabilities ​ Liabilities Balance – Level 3, at December 1, 2021 ​ $ 867,000 ​ $ — Debt extinguishment ​ (127,000) ​ Change in fair value ​ 236,000 ​ Balance – Level 3, at February 28, 2022 ​ 976,000 ​ — Reclassification of warrants from equity to liability due to reassessment under ASC 815 ​ — ​ 903,000 Debt extinguishment ​ (107,000) ​ — Change in fair value ​ 134,000 ​ (129,000) Balance – Level 3, at May 31, 2022 ​ $ 1,003,000 ​ $ 774,000 ​ The fair value of the contingent put option in all outstanding debentures with the feature and derivative liabilities, comprised of warrant liabilities, are revalued as of May 31, 2022 and November 30, 2021 based on the following weighted average key inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ May 31, 2022 ​ November 30, 2021 ​ ​ Embedded Derivative ​ Derivative ​ Embedded Derivative ​ Liabilities Liabilities Liabilities Strike price ​ $ 0.62 ​ $ 0.51 ​ $ 0.71 ​ Terms (years) ​ 0.5 ​ 6.9 ​ 0.8 ​ Volatility ​ 130 % 119 % 71 % Risk-free rate ​ 1.6 % 2.8 % 0.2 % Dividend yield ​ 0 % 0 % 0 % ​

Subsequent Events

Subsequent Events	6 Months Ended
	May 31, 2022
Subsequent Events
Subsequent Events	Note 11 - Subsequent Events On June 8, 2022, the Company issued 975,853 shares of common stock to convert approximately $78,000 of outstanding debt and interest. On June 13, 2022, the Company issued 1,051,376 shares of common stock as dividend payments on Series A and Series B preferred stock. On July 1, 2022, the “Company entered into a Securities Purchase Agreement with 1800 Diagonal Lending LLC, an accredited investor (“DL”) pursuant to which the Company issued to DL a Convertible Promissory Note (the “DL Note”) in the aggregate principal amount of $119,888 for a purchase price of $104,250. The DL Note has a maturity date of July 1, 2023 and the Company has agreed to pay interest on the unpaid principal balance of the DL Note at the rate of ten percent (10.0%) per annum from the date on which the DL Note is issued (the “Issue Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company have the right to prepay the DL Note, provided it makes a payment including a prepayment to DL as set forth in the DL Note. The outstanding principal amount of the DL Note may not be converted prior to the period beginning on the date that is 180 days following the Issue Date. Following the 180th day, DL may convert the DL Note into shares of the Company’s common stock at a conversion price equal to 80% of the average of 3 lowest trading price with a 10-day look back immediately preceding the date of conversion.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	May 31, 2022
Summary of Significant Accounting Policies
Modification of Equity Classified Awards	Modification of Equity Classified Awards From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards. The classification of stock-based awards, including whether such instruments should be recorded as liabilities or as equity, is re-assessed on the modification date.
Induced Conversion of Convertible Preferred Stock	Induced Conversion of Convertible Preferred Stock The Company accounts for gains or losses on extinguishment of equity-classified preferred stock as deemed dividends, to be included in the net loss per common stockholder used to calculate earnings per share. The difference between (1) the fair value of the consideration transferred to the holders of the preferred stock and (2) the carrying amount of the preferred stock (net of issuance costs) is subtracted from (or added to) net loss to arrive at net loss available to common stockholders in the calculation of earnings per share.
Sequencing Policy	Sequencing Policy The Company adopted a sequencing policy under ASC 815-40-35 (“ASC 815”) whereby in the event that reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares as a result of certain financial instruments with a potentially indeterminable number of shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive financial instruments, with the earliest financial instruments receiving the first allocation of shares. Pursuant to ASC 815, issuance of stock-based awards to the Company’s employees, nonemployees or directors recognized under ASC 718 are not subject to the sequencing policy. Any modifications of awards (e.g., options or warrants) that remain subject to vesting, or any modifications of awards that continue to be held by active employees, are not subject to the sequencing policy. Modifications of vested awards held by nonemployees are subject to the sequencing policy.
Recent Accounting Standards	Recent Accounting Standards In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 is not expected to have a material impact on our financial statements or disclosures.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company elected to early adopt this guidance on December 1, 2021, on a modified retrospective basis. The adoption resulted in approximately $291,000 decrease in additional paid in capital from the derecognition of the bifurcated equity component, $208,000 increase in debt from the derecognition of the discount associated with the bifurcated equity component and $83,000 decrease to the opening balance of accumulated deficit.

Loss per share (Tables)

Loss per share (Tables)	6 Months Ended
	May 31, 2022
Loss per share
Schedule of potentially dilutive securities not considered in the computation of diluted net loss per share	​ ​ ​ ​ ​ ​ Potentially dilutive securities May 31, 2022 November 30, 2021 Series A convertible preferred stock ​ 2,280,000 ​ 2,280,000 Series B convertible preferred stock ​ 9,857,000 ​ 11,429,000 Common stock purchase warrants ​ 12,152,000 ​ 11,752,000 Stock Options ​ 4,450,000 ​ 4,450,000 Convertible Notes 34,928,000 4,898,000 Potentially dilutive securities 63,667,000 34,809,000

Debt (Tables)

Debt (Tables)	6 Months Ended
	May 31, 2022
Debt
Schedule of convertible notes payable	The table below summarizes outstanding debt as of May 31, 2022 and November 30, 2021 (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ May 31, 2022 November 30, 2021 Convertible Notes Payable: ​ ​ ​ ​ ​ ​ Principal value of 2021 Debentures ​ $ 2,828,000 ​ $ 3,506,000 Fair value of bifurcated contingent put option ​ 1,003,000 ​ 867,000 Debt discount ​ (466,000) ​ (1,320,000) Convertible notes payable, net ​ ​ 3,365,000 ​ ​ 3,053,000 Cash advances ​ ​ 50,000 ​ ​ — Total debt ​ $ 3,415,000 ​ $ 3,053,000
Schedule of interest expense	Interest expense, included in the accompanying Condensed Consolidated Statements of Operations, is comprised of the following for each period presented (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ For the six months ended ​ May 31, 2022 May 31, 2021 May 31, 2022 May 31, 2021 Interest expense based on the coupon interest rate of the outstanding debt ​ $ 59,000 ​ $ 15,000 ​ $ 120,000 ​ $ 25,000 Accretion of debt discount ​ ​ 391,000 ​ ​ 70,000 ​ ​ 743,000 ​ ​ 110,000 Other ​ ​ 4,000 ​ ​ — ​ ​ 5,000 ​ ​ — Total interest expense ​ $ 454,000 ​ $ 85,000 ​ $ 868,000 ​ $ 135,000

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	May 31, 2022
Related Party Transactions
Schedule of general and administrative expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the three months ended ​ For the six months ended ​ May 31, 2022 May 31, 2021 May 31, 2022 May 31, 2021 Consulting and legal expenses ​ $ 105,000 ​ $ 105,000 ​ $ 210,000 ​ $ 210,000

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	May 31, 2022
Stockholders' Deficit
Schedule original issue price and the liquidation value per share for each class of preferred stock	The original issue price and the liquidation value per share, as of May 31, 2022, of each class of preferred stock is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Original Issue Price Liquidation Value ​ ​ Per Share ​ Per Share Series A Preferred Share ​ $ 10.00 ​ $ 10.20 Series B Preferred Share ​ $ 10.00 ​ $ 10.23

Warrants and Options (Tables)

Warrants and Options (Tables)	6 Months Ended
	May 31, 2022
Common stock purchase warrants
Summary of warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Contractual ​ ​ ​ ​ ​ Warrants ​ Exercise Price ​ Life (years) ​ Intrinsic Value Outstanding at November 30, 2021 11,752,000 ​ $ 1.97 2.60 ​ $ — Issued 400,000 ​ ​ 0.50 2.73 ​ ​ — Forfeited/expired — ​ ​ — — ​ ​ — Outstanding at May 31, 2022 12,152,000 ​ $ 1.40 4.0 ​ $ — Exercisable at May 31, 2022 12,152,000 ​ $ 1.40 4.0 ​ $ —
Schedule of fair value outstanding warrants and options issued to non-employees for services	​ ​ ​ ​ ​ ​ ​ February 22, 2022 Strike price ​ $ 0.50 ​ Terms (years) ​ 3.0 ​ Volatility ​ 126 % Risk-free rate ​ 1.7 % Dividend yield ​ 0.0 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification ​ Strike price ​ $ 0.65 ​ $ 2.33 ​ Term (years) ​ 2.5 ​ 2.1 ​ Volatility ​ 135 % 127 % Risk-free rate ​ 1.0 % 1.0 % Dividend yield ​ 0.0 % 0.0 % The Company immediately recognized approximately $261,000 incremental stock-based compensation during the quarter ended May 31, 2022 based on the following weighted average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification Strike price ​ $ 0.51 ​ $ 1.76 ​ Term (years) ​ ​ 6.9 ​ ​ 2.1 ​ Volatility ​ ​ 118 % ​ 128 % Risk-free rate ​ ​ 2.7 % ​ 2.2 % Dividend yield ​ ​ 0.0 % ​ 0.0 %
Stock Options
Schedule of fair value outstanding warrants and options issued to non-employees for services	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification Strike price ​ $ 0.49 ​ $ 1.13 Term (years) ​ 7.8 ​ 2.8 ​ Volatility ​ 117 % ​ 127 % Risk-free rate ​ 2.7 % ​ 2.4 % Dividend yield ​ 0.0 % ​ 0.0 %
Schedule of Options issued for services	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Remaining Contractual ​ ​ ​ ​ Options Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2021 4,450,000 ​ $ 1.13 4.0 ​ $ 1,000 Issued — ​ ​ — — ​ ​ — Forfeited/expired ​ — ​ ​ — ​ — ​ ​ — Outstanding at May 31, 2022 4,450,000 ​ $ 0.49 7.8 ​ $ — Exercisable at May 31, 2022 4,150,000 ​ $ 0.50 7.7 ​ $ —

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	May 31, 2022
Fair Value Measurements
Schedule of company's liabilities measured at fair value on a recurring basis	The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of May 31, 2022 and November 30, 2021 (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at May 31, 2022 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Fair value at ​ markets ​ observable inputs ​ unobservable inputs ​ May 31, 2022 (Level 1) (Level 2) (Level 3) Embedded derivative liabilities ​ $ 1,003,000 ​ $ — ​ $ — ​ $ 1,003,000 Derivative liabilities ​ $ 774,000 ​ $ — ​ $ — ​ $ 774,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at November 30, 2021 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Fair value at ​ markets ​ observable inputs ​ unobservable inputs ​ November 30, 2021 (Level 1) (Level 2) (Level 3) Embedded derivative liabilities ​ $ 867,000 ​ $ — ​ $ — ​ $ 867,000
Summary of the changes in the fair value of the liabilities, a level 3 liability, measured on recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ Embedded Derivative Derivative ​ ​ Liabilities ​ Liabilities Balance – Level 3, at December 1, 2021 ​ $ 867,000 ​ $ — Debt extinguishment ​ (127,000) ​ Change in fair value ​ 236,000 ​ Balance – Level 3, at February 28, 2022 ​ 976,000 ​ — Reclassification of warrants from equity to liability due to reassessment under ASC 815 ​ — ​ 903,000 Debt extinguishment ​ (107,000) ​ — Change in fair value ​ 134,000 ​ (129,000) Balance – Level 3, at May 31, 2022 ​ $ 1,003,000 ​ $ 774,000
Fair value measurement inputs and valuation techniques	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ May 31, 2022 ​ November 30, 2021 ​ ​ Embedded Derivative ​ Derivative ​ Embedded Derivative ​ Liabilities Liabilities Liabilities Strike price ​ $ 0.62 ​ $ 0.51 ​ $ 0.71 ​ Terms (years) ​ 0.5 ​ 6.9 ​ 0.8 ​ Volatility ​ 130 % 119 % 71 % Risk-free rate ​ 1.6 % 2.8 % 0.2 % Dividend yield ​ 0 % 0 % 0 %

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	6 Months Ended
	May 31, 2022	Nov. 30, 2021
Summary of Significant Accounting Policies
Decrease in additional paid in capital	$ 291,000
Increase in debt from derecognition of discount associated with bifurcated equity component	208,000
Decrease to opening balance of accumulated deficit	83,000
Net carrying value	$ 325,000	$ 350,000

Loss per share (Details)

Loss per share (Details) - shares	6 Months Ended	12 Months Ended
	May 31, 2022	Nov. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	63,667,000	34,809,000
Series A convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	2,280,000	2,280,000
Series B convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	9,857,000	11,429,000
Common stock purchase warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	12,152,000	11,752,000
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	4,450,000	4,450,000
Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	34,928,000	4,898,000

Debt (Details)

Debt (Details) - USD ($)	May 31, 2022	Nov. 30, 2021
Convertible Notes Payable:
Convertible notes payable, net	$ 3,365,000	$ 3,053,000
Cash advances	50,000
Total debt	3,415,000	3,053,000
2021 Debentures
Convertible Notes Payable:
Principal value	2,828,000	3,506,000
Fair value of bifurcated contingent put option	1,003,000	867,000
Debt discount	$ (466,000)	$ (1,320,000)

Debt - Interest expense (Detail

Debt - Interest expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021
Debt
Interest expense based on the coupon interest rate of the outstanding debt	$ 59,000	$ 15,000	$ 120,000	$ 25,000
Accretion of debt discount	$ 391,000	$ 70,000	$ 743,000	$ 110,000
Other	4,000	—	5,000	—
Total interest expense	$ 454,000	$ 85,000	$ 868,000	$ 135,000

Debt - Additional Information (

Debt - Additional Information (Details)								3 Months Ended		6 Months Ended
	May 12, 2022 USD ($) shares	Apr. 08, 2022 USD ($) shares	Jan. 21, 2022 USD ($) $ / shares shares	Dec. 15, 2021 USD ($)	Sep. 29, 2021 USD ($) item $ / shares	Jul. 26, 2021 USD ($) item D $ / shares shares	Feb. 12, 2021 USD ($) D item $ / shares	May 31, 2022 USD ($) shares	May 31, 2021 USD ($)	May 31, 2022 USD ($) shares	May 31, 2021 USD ($)
Debt Instruments [Line Items]
Conversion price | $ / shares			$ 0.50
Shares issued, conversion of debt | shares			1,055,000					1,162,790		1,685,438
Amount of debt converted			$ 500,000					$ 100,000		$ 300,000
Loss on debt extinguishment								$ 0	$ 0	$ (232,100)	$ (56,122)
Increase in outstanding principal balance				$ 241,875
Warrants exercisable term								5 years		5 years
Stock Issued During Period, Value, Conversion of Convertible Securities								$ 282,797		$ 1,336,744	$ 203,014
2021 Debentures
Debt Instruments [Line Items]
Issue Of Debentures, Amount						$ 806,250	$ 500,000
Conversion price | $ / shares					$ 1
Percentage of average of the four lowest daily VWAPs on basis of which conversion price is reduced					85%	85%	93%
Number of lowest daily VWAPs during the 10 consecutive trading days on basis of which conversion price is reduced | item					4	4	4
Number of consecutive trading days					10	20	10
Interest rate (as percent)					6%	10%	5.50%
Commitment fee (as percent)							2%
Number of warrants issued | shares						645,000
Total purchase price						$ 750,000
Default interest rate						15%
Percent of prepayment within first 60 days of issuance					105%	120%
Percent of prepayment from 61 to 180 days after issuance						130%
Percent of prepayment from 61-120 days after issuance					112%
Carrying value of convertible notes					$ 2,200,000
Maturity period (in months)					12 months
Original issue discount					$ 185,000
Issuance costs					$ 15,000			$ 247,350		$ 247,350
Percent of prepayment from 121 to 180 days after issuance					124%
Conversion price after six months | $ / shares					$ 0.50
Number of prior trading days in conversion price | item					20
Floor price of debentures | $ / shares						$ 0.35
Readjusted initial Floor Price | $ / shares						0.10
Minimum price of VWAP to be satisfied for Adjustment for at least 10 days | $ / shares						$ 0.35
Number of days at least VWAP should be $0.35						10 days
Stock Issued During Period, Shares, Commitment Fee | shares		245,000
Stock Issued During Period, Value, Commitment Fee		$ 200,000
Issuance of additional common stock to convertible notes holders, Shares | shares	726,903
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 100,000
2021 Debentures | Maximum
Debt Instruments [Line Items]
Conversion price | $ / shares						$ 1	$ 1.15
2021 Debentures | Minimum
Debt Instruments [Line Items]
Conversion price | $ / shares							$ 1

Commitments and Contingencies (

Commitments and Contingencies (Details)			1 Months Ended
	Jul. 12, 2022 USD ($)	Mar. 11, 2022 USD ($)	Mar. 31, 2022 USD ($) item	Dec. 31, 2016 USD ($)
Loss Contingencies [Line Items]
Damages sought			$ 106,000
Number of master services agreements | item			2
Lease agreement
Loss Contingencies [Line Items]
Lease cost per annum				$ 30,000
Renewal term (in years)				3 years
Advisory Agreements | EF Hutton
Loss Contingencies [Line Items]
Bridge or Other Private Offering Value		$ 2,000,000
Advisory Agreements | EF Hutton | Maximum
Loss Contingencies [Line Items]
External counsel legal costs		$ 50,000
Master Professional Services Agreement | WSI PBG, LLC
Loss Contingencies [Line Items]
Damages sought	$ 196,216

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021
Related Party Transactions
Consulting and legal expenses	$ 105,000	$ 105,000	$ 210,000	$ 210,000

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - $ / shares	May 31, 2022	Nov. 30, 2021
Stockholders' Deficit
Common stock, shares authorized	250,000,000	250,000,000
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, par value	$ 0.001	$ 0.001
Number of preferred shares authorized	100,000,000	100,000,000

Stockholders' Deficit - Preferr

Stockholders' Deficit - Preferred Shares (Details) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021	Feb. 14, 2022
Original Issue Price Per Share					$ 0.25
Number of common stock issued to convert Series B preferred stock	4,972,797		4,972,797
Number of shares converted	55,000		55,000
Deemed dividend for induced conversion of convertible preferred stock	$ 507,927	$ 0	$ 507,927	$ 0
Series A convertible preferred stock
Original Issue Price Per Share	$ 10		$ 10
Liquidation Value Per Share	10.20		10.20
Series B convertible preferred stock
Original Issue Price Per Share	10		10
Liquidation Value Per Share	$ 10.23		$ 10.23
Preferred stock
Accumulated dividend on preferred stock			$ 100,000
Common Stock
Issuance common stock for dividend payment on series A and series B preferred stock	402,563		680,440

Stockholders' Deficit - Common

Stockholders' Deficit - Common Shares (Details) - USD ($)		3 Months Ended		6 Months Ended
	Feb. 14, 2022	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021
Issuance of common stock and warrants for cash (in shares)	400,000
Original Issue Price Per Share	$ 0.25
Proceeds from sale of securities	$ 100,000		$ 910,000	$ 100,030	$ 910,000
Number of common stock shares in unit	1			3,467,341
Number of warrants issued per unit	1
Number of shares issuable per warrants	1
Exercise price	$ 0.50
Fair Value of Warrants Per Share	$ 0.28
Outstanding debt and interest				$ 900,000
Share based compensation for services, Amount		$ 72,079	592,489	$ 223,594	1,953,583
Shares issued upon conversion of accrued expenses		55,000		55,000
Loss on debt extinguishment		$ 0	$ 0	$ (232,100)	$ (56,122)
Advisory services
Number of common stock shares in unit				132,381
Common Stock
Issuance of common stock and warrants for cash (in shares)			1,213,333	400,000	1,213,333
Proceeds from sale of securities			$ 1,213	$ 400	$ 1,213
Number of common stock shares in unit		1,889,693
Shares issued for conversion		1,889,693		3,467,341	167,780
Outstanding debt and interest		$ 200,000
Share based compensation for services, Shares		37,456	120,832	132,381	623,808
Share based compensation for services, Amount		$ 37	$ 121	$ 132	$ 624
Change in fair value of embedded derivatives				200,000
Loss on debt extinguishment				200,000
Common Stock | Stock Options and Restricted Stock
Share based compensation for services, Amount		62,000		171,000
Common Stock | Advisory services
Proceeds from sale of securities		$ 10,000		$ 53,000
Number of common stock shares in unit		37,456
Series B convertible preferred stock
Original Issue Price Per Share		$ 10		$ 10
General and Administrative Expense | Common Stock
Share based compensation for services, Amount		$ 72,000		$ 224,000

Warrants and Options - Summary

Warrants and Options - Summary of warrants (Details) - Common stock purchase warrants - $ / shares		6 Months Ended
	Nov. 30, 2021	May 31, 2022
Warrants
Beginning balance		11,752,000
Issued		400,000
Ending balance	11,752,000	12,152,000
Exercisable at February 28, 2022		12,152,000
Weighted Average Exercise Price
Beginning balance		$ 1.97
Issued		0.50
Ending balance	$ 1.97	$ 1.40
Exercisable at February 28, 2022		1.40
Weighted Average Remaining Contractual Life (years)
Beginning balance	2 years 7 months 6 days
Issued		2 years 8 months 23 days
Forfeited/expired		0 years
Ending balance		4 years
Exercisable at February 28, 2022		4 years

Warrants and Options - Fair val

Warrants and Options - Fair value of warrants and Modification of warrants (Details) - $ / shares			3 Months Ended
	Feb. 22, 2022	Feb. 01, 2022	May 31, 2022
Common stock purchase warrants | After Modification
Strike price		$ 0.65	$ 0.51
Term (years)		2 years 6 months	6 years 10 months 24 days
Volatility		135%	118%
Risk-free rate		1%	2.70%
Dividend yield		0%	0%
Common stock purchase warrants | Before Modification
Strike price		$ 2.33	$ 1.76
Term (years)		2 years 1 month 6 days	2 years 1 month 6 days
Volatility		127%	128%
Risk-free rate		1%	2.20%
Dividend yield		0%	0%
Stock Options
Strike price	$ 0.50
Term (years)	3 years
Volatility	126%
Risk-free rate	1.70%
Dividend yield	0%
Stock Options | After Modification
Strike price			$ 0.49
Term (years)			7 years 9 months 18 days
Volatility			117%
Risk-free rate			2.70%
Dividend yield			0%
Stock Options | Before Modification
Strike price			$ 1.13
Term (years)			2 years 9 months 18 days
Volatility			127%
Risk-free rate			2.40%
Dividend yield			0%

Warrants and Options - Addition

Warrants and Options - Additional Information (Details) - USD ($)			2 Months Ended	3 Months Ended		6 Months Ended
	May 25, 2022	Feb. 01, 2022	May 31, 2022	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021	Feb. 14, 2022
Number of modified warrants		245,625	4,765,807
Exercise price of warrant								$ 0.50
Warrants exercisable term			5 years	5 years		5 years
Exercise price of options	$ 0.50
Options vested	4,150,000
Options term	5 years
Incremental aggregate stock-based compensation related to modifications	$ 188,000	$ 17,000		$ 261,000
Incremental stock-based compensation				179,000
Number of modified warrants to purchase common shares upon reclassification from equity to liability						5,411,432
General and administrative expenses				1,019,168	$ 1,519,660	$ 2,115,468	$ 3,656,992
Unrecognized stock-based compensation			$ 52,000,000,000	$ 52,000,000,000		$ 52,000,000,000
Minimum
Exercise price of warrant			$ 0.50	$ 0.50		$ 0.50
Maximum
Exercise price of warrant			$ 0.65	$ 0.65		$ 0.65
Officers, directors and certain consultants
Number of options modified	4,450,000
After Modification
Exercise price of warrant		$ 0.65
Number of options modified						4,150,000
Amount of consideration received						$ 20,000
Options And Warrants [Member]
General and administrative expenses				$ 200,000	$ 1,400,000	$ 200,000	$ 2,000,000

Warrants and Options - Summar_2

Warrants and Options - Summary of outstanding options (Details) - Stock Options		6 Months Ended
	Nov. 30, 2021 $ / shares shares	May 31, 2022 $ / shares shares
Options
Beginning balance | shares		4,450,000
Ending balance | shares	4,450,000	4,450,000
Exercisable at February 28, 2022 | shares		4,150,000
Weighted Average Exercise Price
Beginning balance		$ 1.13
Ending balance	$ 1.13	$ 0.49
Exercisable at February 28, 2022		0.50
Weighted Average Remaining Contractual Life (years)
Beginning balance	4 years
Issued		0 years
Ending balance		7 years 9 months 18 days
Exercisable at February 28, 2022		7 years 8 months 12 days
Intrinsic Value
Beginning balance	$ 1,000

Fair Value Measurements - Liabi

Fair Value Measurements - Liabilities measured at fair value on a recurring basis (Details) - Recurring - USD ($)	May 31, 2022	Nov. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Embedded derivative liabilities	$ 1,003,000	$ 867,000
Derivative liabilities	774,000
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Embedded derivative liabilities	1,003,000	$ 867,000
Derivative liabilities	$ 774,000

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 liabilities measured at fair value (Details) - USD ($)	3 Months Ended
	May 31, 2022	Feb. 28, 2022
Embedded Derivative Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance - Level 3, at beginning	$ 976,000	$ 867,000
Debt extinguishment	(107,000)	(127,000)
Change in fair value	134,000	236,000
Balance - Level 3, at ending	1,003,000	$ 976,000
Derivative liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Reclassification of warrants from equity to liability due to reassessment under ASC 815	903,000
Change in fair value	(129,000)
Balance - Level 3, at ending	$ 774,000

Fair Value Measurements - Measu

Fair Value Measurements - Measurement inputs (Details)	May 31, 2022 Y $ / shares	Nov. 30, 2021 Y $ / shares
Strike price | Embedded Derivative Liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input | $ / shares	0.62	0.71
Strike price | Derivative liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input | $ / shares	0.51
Terms (years) | Embedded Derivative Liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input | Y	0.5	0.8
Terms (years) | Derivative liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input | Y	6.9
Volatility | Embedded Derivative Liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	130	71
Volatility | Derivative liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	119
Risk-free rate | Embedded Derivative Liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	1.6	0.2
Risk-free rate | Derivative liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	2.8
Dividend yield | Embedded Derivative Liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Dividend yield | Derivative liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0

Fair Value Measurements - Addit

Fair Value Measurements - Additional information (Details) - USD ($)	3 Months Ended	6 Months Ended
	May 31, 2022	May 31, 2022
Fair Value Measurements
Fair value recognized	$ 123,000	$ 123,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)					3 Months Ended	6 Months Ended
	Jul. 01, 2022	Jun. 13, 2022	Jun. 08, 2022	Jan. 21, 2022	May 31, 2022	May 31, 2022	May 31, 2021
Subsequent Event [Line Items]
Shares issued, conversion of debt				1,055,000	1,162,790	1,685,438
Amount of debt converted				$ 500,000	$ 100,000	$ 300,000
Proceeds received from issuance of convertible note						$ 0	$ 975,000
Subsequent Event
Subsequent Event [Line Items]
Shares issued, conversion of debt			975,853
Amount of debt converted			$ 78,000,000
Number of shares issued upon dividend payments		1,051,376
Subsequent Event | Debentures.
Subsequent Event [Line Items]
Principal value	$ 119,888,000
Proceeds received from issuance of convertible note	$ 104,250,000
Interest rate (as percent)	10%
Debt conversion term	180 days
Conversion price percentage	80%
Look back period	10 days